ClinicalTrials.gg
RecruitingNCT06120218TOESISUpdated Jun 13, 2024

Tandem Occlusion After Emergent Stenting in Acute Ischemic Stroke

An interventional study of Emergent Stenting in Acute Stroke and Ischemic Stroke, Acute, sponsored by Can Tho Stroke International Services Hospital. Recruiting at 1 site in Vietnam. Open to participants aged 19 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-06-13.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Can Tho Stroke International Services Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Registered 2 years 11 months after the study started (first participant enrolled Dec 2020, registered Nov 2023).
  • Started Dec 2020; still recruiting 5 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
19 Years to 100 Years
Sex
All
01

Study summary

In acute ischemic stroke due to tandem occlusion, the emergent stenting has recently become an endovascular treatment option combining with mechanical thrombectomy to achieve recanalization. However, the data on the beneficial endovascular management of tandem occlusion in two circulations is still limited. The purpose of our study was to compare the improvement of clinical outcome between two circulations after emergent stenting at 3 months.

Read the detailed description

The posterior circulation (about 20 - 25%) is less frequent than the anterior one in the acute ischemic stroke, but high mortality and morbidity in the acute vertebrobasilar thrombosis even successful recanalization are revealed. Besides, tandem occlusion is one of the complex lesions in large vessel occlusions relating to the poor outcome, particularly in the posterior circulation. Recent studies have suggested that emergent stenting could be used as an additional treatment to achieve permanent recanalization together with mechanical thrombectomy in the intracranial segments. Permanent recanalization is one of the most important factors that impact patient outcomes after acute ischemic stroke. However, although there are various approaches for this lesion, the comparision of the effectiveness in the two circulations remains unclear. Thus, the aims of our study were to compare baseline characteristics and clinical outcome of tandem occlusions between anterior and posterior circulation after emergent stenting in extracranial arteries.

02

Conditions studied

  • Acute Stroke
  • Ischemic Stroke, Acute

Browse trials for

Keywords

  • Thrombectomy
  • Extracranial arteries
  • Endovascular treatment
  • Antegrade approach
  • Retrograde approach
03

In context

Ischemic Stroke Reclassified

2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.

This study's planned enrollment of 110 is close to the median of 120 across 1,776 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Can Tho Stroke International Services Hospital is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
19 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years old
  • Premorbid mRS \< 2
  • NIHSS > 5
  • ASPECTS ≥ 5 or pc-ASPECTS ≥ 5

Exclusion criteria

Exclusion Criteria:

  • Onset to treatment time > 24 hours
  • Loss to follow up after discharge
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Emergent Stenting in Anterior circulation

    Emergent Carotid Stenting in acute ischemic stroke caused by tandem occlusions

    Procedure: Emergent Stenting

  • Experimental
    Emergent Stenting in Posterior circulation

    Emergent Extracranial Vertebral Stenting in acute ischemic stroke caused by tandem occlusions

    Procedure: Emergent Stenting

Interventions

  • ProcedureEmergent Stenting

    Emergent Stenting in acute ischemic stroke caused by tandem occlusions

06

What researchers measure

Primary outcomes

  1. The favorable 3-month outcome rate

    The favorable 3-month outcome rate was accessed by modified Rankin Score (mRS), which comprised of included good (mRS 0 - ≤ 2) and fair (mRS 3).

    Time frame: 3 months

Secondary outcomes

  1. The symptomatic intracerebral hemorrhage rate

    The symptomatic intracerebral hemorrhage was defined as patient's intracerebral hemorrhage with postprocedural mRS ≥ 5 and there were no other evident causes for the increased modified Rankin Score (mRS).

    Time frame: 24 hours after emergent stenting

07

Study locations

1 of 1 sites recruiting
  • Can Tho Stroke International Services Hospital
    Can Tho, 900000, Vietnam
    Recruiting
08

References and documents

Publications

  • Allard J, Delvoye F, Pop R, Labreuche J, Maier B, Marnat G, Sibon I, Zhu F, Lapergue B, Consoli A, Spelle L, Denier C, Richard S, Piotin M, Gory B, Mazighi M; ETIS Investigators. 24-Hour Carotid Stent Patency and Outcomes After Endovascular Therapy: A Multicenter Study. Stroke. 2023 Jan;54(1):124-131. doi: 10.1161/STROKEAHA.122.039797. Epub 2022 Dec 21. PubMed 36542074 ↗
  • Han N, Ma L, Zhao L, Xu G, Jia Y, Wang H. The Dilator-Dotter technique can successfully treat tandem lesions of posterior circulation. Medicine (Baltimore). 2024 Jan 26;103(4):e37044. doi: 10.1097/MD.0000000000037044. PubMed 38277540 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Sep 2025, 57 months after the start.

Of 572 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 57 months is above that.

Counting every sponsor, half of 653 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2023
First posted
Nov 7, 2023
StartActual
Dec 1, 2020
Primary completionEst.
Sep 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06120218
Lead sponsor
Can Tho Stroke International Services Hospital
Responsible party
Dr. Cuong Tran Chi (Director, Can Tho Stroke International Services Hospital) — Principal investigator
First posted
Nov 7, 2023
Start date
Dec 1, 2020
Primary completion
Sep 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Jun 13, 2024

Study contacts

Cuong Tran Chi, Doctor
Contact
drcuongtran@dotquy.vn
+84886559911
Can Tho Stroke International Services Hospital
Contact
cskh@dotquy.vn
+84886559911
Cuong Tran Chi, Doctor
study director · Can Tho Stroke International Services General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion